[Increase of immunoglobulins and formation of antibodies in the course of asparaginase treatment].
D000293:Adolescent; D000328:Adult; D000368:Aged; D000917:Antibody Formation / Q000187:drug effects*; D001215:Asparaginase / Q000494:pharmacology / Q000627:therapeutic use*; D001796:Blood Protein Disorders / Q000188:drug therapy; D002528:Cerebellar Neoplasms / Q000188:drug therapy; D002648:Child; D004885:Erwinia; D004926:Escherichia coli; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D007153:Immunologic Deficiency Syndromes / Q000188:drug therapy*; D007938:Leukemia / Q000188:drug therapy*; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D008199:Lymphadenitis / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D012509:Sarcoma / Q000188:drug therapy
D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D001215:Asparaginase
Immunglobulinvermehrung und Antikörperbildung unter Asparaginase-Therapie.